Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Case of Chronic Myelomonocytic Leukemia With Recurrent Skin Involvement.
Cureus
December 2024
Pathology Department, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, TUR.
Article Synopsis
- Chronic myelomonocytic leukemia (CMML) is a complex blood cell disorder that combines poorly functioning and overproducing blood cells, leading to various symptoms.
- The case study focuses on a 71-year-old man with severe CMML who experienced skin nodules that improved with treatment but later recurred, while avoiding progression to acute leukemia.
- The findings emphasize the importance of close monitoring and flexible treatment approaches for patients with CMML, especially those with skin involvement.
An Overview of Myeloid Blast-Phase Chronic Myeloid Leukemia.
Cancers (Basel)
October 2024
Office of Oncologic Diseases, Center for Drug Evaluation and Research-CDER, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
Myeloid blast-phase chronic myeloid leukemia (MBP-CML) is a rare disease with a dismal prognosis. It is twice as common as lymphoid blast-phase CML, and its prognosis is poorer. Despite the success with tyrosine kinase inhibitors in the treatment of chronic-phase CML, the same does not hold true for MBP-CML.
View Article and Find Full Text PDFBPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.
JCI Insight
December 2024
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
MYB fusions are recurrently found in select cancers, including blastic plasmacytoid DC neoplasm (BPDCN), an acute leukemia with poor prognosis. They are markedly enriched in BPDCN compared with other blood cancers and, in some patients, are the only obvious somatic mutation detected. This suggests that they may alone be sufficient to drive DC transformation.
View Article and Find Full Text PDFArticle Synopsis
- Chronic myeloid leukemia (CML) can develop from a chronic phase to a rare megakaryoblastic phase, which has a poor prognosis and resistance to standard treatments like tyrosine kinase inhibitors (TKIs).
- A case study details a 39-year-old woman whose CML progressed to this rare phase despite receiving chemotherapy, leading to her death within a month.
- The diagnosis included various tests showing that the disease transformed into acute megakaryoblastic leukemia (AMKL), emphasizing the importance of using megakaryocytic markers in diagnosis for better treatment outcomes.
Venetoclax is effective for chronic myelomonocytic leukemia blastic transformation with mutation.
Hematology
December 2024
Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Chronic myelomonocytic leukemia is a clonal hematological disorder with an inherent risk of transformation to acute myeloid leukemia. Recently, there has been exponential discovery of molecular abnormalities in patients with chronic myelomonocytic leukemia. Some of these mutations independently contribute to a higher risk of transformation and result in inferior overall survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!